Epigenetic inhibitors attenuate pathological gene expression in cardiomyocytes

Epigenetic modulators have been proposed as promising new drug targets to treat adverse remodeling in heart failure. Here, we evaluated the potential of 4 epigenetic drugs, including the pan-BRD (bromodomain-containing ...

BJP Themed Issue: Therapeutic targeting of the aldosterone–mineralocorticoid receptor signaling pathway

During the past few years enormous research activities substantially advanced our understanding of the molecular, cellular, and pathophysiological functions of the MR. The British Journal of Pharmacology now publishs a ...

Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms

MR antagonists have proven to be highly efficient in patients with heart failure and reduced ejection fraction, and they are a cornerstone of contemporary therapy. In the past decade, a series of ...
DFG

DFG supports scientific network on Aldosterone-Mineralocorticoid receptor signaling

The German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) supports the formation of a scientific network on ‘Strategies for therapeutic targeting of the Aldosterone-Mineralocorticoid Receptor signaling pathway’ (Speaker: Achim Lother). The network ...

Approaches towards tissue-selective pharmacology of the mineralocorticoid receptor

Mineralocorticoid receptor antagonists (MRAs) are highly effective therapies for cardiovascular and renal disease. However, the widespread clinical use of currently available MRAs in cardiorenal medicine is hampered by an increased ...

Reviewed: MR in pulmonary hypertension and RV failure

Pulmonary hypertension (PH) is characterized by pulmonary vascular remodelling, leading to progressive increase in pulmonary artery pressure and subsequent right ventricular failure. Aldosterone and the mineralocorticoid receptor (MR) are key ...